AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model
about
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translationProspects for gene transfer for clinical heart failureGRK2 in the heart: a GPCR kinase and beyondCardiovascular gene therapy for myocardial infarctionAllogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathyStructural and Functional Analysis of G Protein-Coupled Receptor Kinase Inhibition by Paroxetine and a Rationally Designed Analog"Freeze, Don't Move": How to Arrest a Suspect in Heart Failure - A Review on Available GRK2 InhibitorsAdeno-associated virus-mediated gene therapy in cardiovascular diseaseThe expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development.Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications.The role of G protein coupled receptor kinases in neurocardiovascular pathophysiologyThe potential of adeno-associated viral vectors for gene delivery to muscle tissue.Identification and structure-function analysis of subfamily selective G protein-coupled receptor kinase inhibitorsMolecular basis for small molecule inhibition of G protein-coupled receptor kinasesMethods to improve cardiac gene therapy expression.Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.The evolving impact of g protein-coupled receptor kinases in cardiac health and diseaseStructure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer.Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarctionMyocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases.Gene transfer for congestive heart failure: update 2013.Cardiac Fibrosis: The Fibroblast AwakensAAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility.Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients With Heart FailureGRK2 in Lymphocytes: Expanding the Arsenal of Heart Failure Prognostics.GRK 2 level in peripheral blood lymphocytes of elderly patients with acute myocardial infarctionA peptide of the RGS domain of GRK2 binds and inhibits Gα(q) to suppress pathological cardiac hypertrophy and dysfunction.An emerging adeno-associated viral vector pipeline for cardiac gene therapyAdrenergic nervous system in heart failure: pathophysiology and therapy.Structural insights into G protein-coupled receptor kinase function.Cardiac progenitor cells engineered with βARKct have enhanced β-adrenergic tolerance.Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium.Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapyG protein-coupled receptor kinase 2 promotes cardiac hypertrophyβ-adrenergic receptor signalling and its functional consequences in the diseased heart.From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart FailureIntegrating GRK2 and NFkappaB in the Pathophysiology of Cardiac Hypertrophy.Neurohormonal activation in heart failure with reduced ejection fraction.GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.
P2860
Q26799437-90665CE8-C7D4-405C-8A6B-E10C4D83FD6FQ26830145-620CB515-5438-42E4-BFF3-0537430D5047Q26851548-8AF4485C-131C-4811-9698-9009B53E2500Q27014770-C965E5A5-70AB-4207-AB25-CE943C88CD16Q27322954-B5CCBDB5-67FE-465B-8E44-D2077E90C282Q27680587-D4BBEBC2-56CC-4A88-9ECA-2E31AD7417E5Q28078766-B6D48F80-A8BD-4549-B4D2-5B99B7C38D0BQ28081681-E93D029D-9607-4559-A95B-0DB3C7176662Q30250314-932D303A-80F9-4441-9F16-297B0C671A2AQ30427066-66A43EF8-AB3B-4E5E-B7B4-4ECE8B11C154Q30459130-102AD757-DA35-4C47-B01D-398BA90CDBABQ33902499-16938C5E-4D22-4166-8916-4A4408FB04DFQ34992323-E14E80F4-7DE6-4551-99FA-9559105B8A55Q34992803-F7936F6B-CD99-4F08-B2C3-089A3ACE0391Q35360600-11773661-1D22-42C3-AF22-8D87DE1A8489Q35981205-B9334601-038C-46CC-9BBE-CCC0DD26A6A6Q36000382-CD3EB902-103B-40D5-AF75-68BAE94904ACQ36316194-B5613B8A-DC7A-4804-ABA7-A70E7FEC0F21Q36563927-0F1CC5E6-C1D4-42A2-A4B7-9EB05B681112Q36623426-CB1DABAF-5908-44E6-B752-598B26DCCCCEQ36651023-D4614E6E-24D1-4399-B90F-E40C8780E3CDQ36698991-8AD7C182-9A02-4D29-817C-CE1712230885Q36708340-CBC002F9-0A93-4535-9049-442B7B8E11B0Q36756838-C9FA85E1-B6EA-4C87-B379-08B318CA9D11Q36757784-081F9C6A-6960-4A75-BE08-BD0CEE906226Q36760778-FF507EE3-0EAB-4DEC-BE19-9AAD986E3452Q37229933-85752FD9-4F3E-42F5-B145-9660889FBAEBQ37241927-E34302D4-8514-4D44-AAE8-2AD4C09213F8Q37272838-267B37DF-1574-40D7-BB98-349C6D411218Q37349756-9EC3399D-E455-4650-A8E5-33478E360213Q37676935-0FD87F34-B354-4E80-943F-C1C7C027C592Q37690449-FC6F2012-3322-4F73-BC5D-40A832B221A0Q38132253-BD38B12F-4E6F-4BCA-9758-406191D1AD10Q38153376-63F8B6C1-39AE-4AF5-94FF-699FFB64DDBBQ38651555-A03F704A-E9AA-4583-B1B7-4199F3D280DBQ38722030-A492E483-DB16-4BC8-BB18-891CBBB35A68Q38780801-10502137-77AC-4AEB-B7A0-797E1F958CBAQ38848001-8EB4160D-52A3-4000-ADEC-1DD8A5C21F7EQ38973209-C9FDE441-E21E-4C63-97E0-648F7440FB93Q39080324-E07C524A-0CC0-4087-B819-DFA778492F55
P2860
AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@ast
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@en
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@nl
type
label
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@ast
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@en
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@nl
prefLabel
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@ast
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@en
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@nl
P2093
P2860
P356
P1476
AAV6.βARKct cardiac gene thera ...... rge animal heart failure model
@en
P2093
Hugo A Katus
Jan Ksienzyk
Jens Barthelmes
Julia Reinkober
Oliver J Müller
Patrick Most
Philip W J Raake
Philipp Schlegel
Stefanie Schinkel
Sven Pleger
P2860
P304
P356
10.1093/EURHEARTJ/EHR447
P50
P577
2012-01-19T00:00:00Z